|
KMID : 0358320150560090624
|
|
Korean Journal of Urology
2015 Volume.56 No. 9 p.624 ~ p.629
|
|
|
Pathological upgrading in prostate cancer patients eligible for active surveillance: Does prostate-specific antigen density matter?
|
|
Jin Byung-Soo
Kang Seok-Hyun
Kim Duk-Yoon
Oh Hoon-Gyu
Kim Chun-Il
Moon Gi-Hak
Kwon Tae-Gyun
Park Jae-Shin
|
|
|
Abstract
|
|
|
Purpose: To evaluate prospectively the role of prostate-specific antigen (PSA) density in predicting Gleason score upgrading in prostate cancer patients eligible for active surveillance (T1/T2, biopsy Gleason score≤6, PSA≤10 ng/mL, and ≤2 positive biopsy cores).
Materials and Methods: Between January 2010 and November 2013, among patients who underwent greater than 10-core transrectal ultrasound-guided biopsy, 60 patients eligible for active surveillance underwent radical prostatectomy. By use of the modified Gleason criteria, the tumor grade of the surgical specimens was examined and compared with the biopsy results.
Results: Tumor upgrading occurred in 24 patients (40.0%). Extracapsular disease and positive surgical margins were found in 6 patients (10.0%) and 8 patients (17.30%), respectively. A statistically significant correlation between PSA density and postoperative upgrading was found (p=0.030); this was in contrast with the other studied parameters, which failed to reach significance, including PSA, prostate volume, number of biopsy cores, and number of positive cores. Tumor upgrading was also highly associated with extracapsular cancer extension (p=0.000). The estimated optimal cutoff value of PSA density was 0.13 ng/mL2, obtained by receiver operating characteristic analysis (area under the curve=0.66; p=0.020; 95% confidence interval, 0.53-0.78).
Conclusions: PSA density is a strong predictor of Gleason score upgrading after radical prostatectomy in patients eligible for active surveillance. Because tumor upgrading increases the potential for postoperative pathological adverse findings and prognosis, PSA density should be considered when treating and consulting patients eligible for active surveillance.
|
|
|
KEYWORD
|
|
|
Neoplasm grading, Prostate specific antigen, Prostatectomy
|
|
|
FullTexts / Linksout information
|
|
 
|
|
|
Listed journal information
|
|
  
|
|